Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LifeTech Scientific Corporation ( (HK:1302) ) just unveiled an update.
LifeTech Scientific Corporation has announced the official registration approval from the China National Medical Products Administration for its Aortic Arch Stent Graft System, a pioneering product aimed at aortic arch branch reconstruction using the fenestration technique. This approval marks a significant milestone in the company’s product portfolio, enhancing its position in the peripheral vascular intervention field. The system, which includes the Ankura™ Plus and CSkirt™ components, demonstrated high success rates and safety in clinical studies, and is expected to provide a comprehensive and effective solution for aortic dissection lesions. The launch is anticipated to drive further development and commercialization of innovative medical devices, benefiting a wide range of patients.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation operates in the medical devices industry, focusing on peripheral vascular intervention solutions. The company develops innovative products for endovascular repair, with a particular emphasis on aortic dissection treatments.
Average Trading Volume: 26,419,412
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.69B
Find detailed analytics on 1302 stock on TipRanks’ Stock Analysis page.